MBX MBX Biosciences, Inc.

NASDAQ
$53.10

MBX Biosciences, Inc. (MBX) is expected to report earnings on February 8, 2027, before the market open. The consensus earnings estimate is a loss of $0.95 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.1% since its last earnings release on November 9, 2026.

MBX Biosciences Missed Consensus Estimates
Monday, November 9, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 8
Monday · 8:00 AM ET
Earnings Whisper
-
vs ($0.95)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $55.62

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About MBX Biosciences, Inc.

MBX Biosciences Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company's pipeline includes its lead product candidate MBX 2109, MBX 1416 and MBX 4291. MBX Biosciences Inc. is based in CARMEL, Ind.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.